Drug

Oxaliplatin clinical trials

Also written Eloxatin, L-OHP and NSC-266046.

studies test it: 855
open now: 116
in phase 3: 138
first study started: 1998

Counted the way a researcher would: Oxaliplatin with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses Oxaliplatin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Oxaliplatin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: 9 Aug 2002 · ELOXATIN · NDA 021492 (FDA, Drugs@FDA)
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Oxaliplatin: 591
Dacplat: 33
1-OHP: 32
Dacotin: 32
Leucovorin: 10

Brand

Eloxatin: 156

Development codes

L-OHP: 33
NSC-266046: 4

In one entry with another drug

Given together, or one or the other

POF: 6
Capecitabine and Oxaliplatin: 6
SOX: 6
Gemcitabine and Oxaliplatin: 5
Oxaliplatin, Capecitabine: 4
FLOT: 3
Capecitabine, Oxaliplatin: 3
Docetaxel, Oxaliplatin: 3

Studies by the year they started

852 studies that test it; most in 2004 (67)

Studies that test Oxaliplatin, by start year
Year	Studies
1998	4
1999	18
2000	28
2001	9
2002	19
2003	37
2004	67
2005	56
2006	62
2007	44
2008	39
2009	33
2010	30
2011	44
2012	24
2013	27
2014	23
2015	30
2016	21
2017	20
2018	22
2019	30
2020	22
2021	24
2022	22
2023	24
2024	22
2025	29
2026	22

By phase

A phase 1/2 study counts in both.

Early Phase 1: 4
Phase 1: 171
Phase 2: 590
Phase 3: 138
Phase 4: 12
No phase: 23

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Colorectal Neoplasms: 168
Stomach Neoplasms: 96
Pancreatic Neoplasms: 68
Rectal Neoplasms: 64
Colonic Neoplasms: 27
Esophageal Neoplasms: 26
Carcinoma, Hepatocellular: 24
Carcinoma, Non-Small-Cell Lung: 19
Lymphoma, Large B-Cell, Diffuse: 12
Biliary Tract Neoplasms: 12
Breast Neoplasms: 12
Cholangiocarcinoma: 11

Who runs them

Industry 103 · Other 752

National Cancer Institute (NCI) (39) · Sanofi (35) · M.D. Anderson Cancer Center (22) · Sun Yat-sen University (20) · Hoffmann-La Roche (19) · GERCOR - Multidisciplinary Oncology Cooperative Group (15) · Fudan University (14) · UNICANCER (14)

Often tested with

Tested in the same studies.

Fluorouracil (241) · Capecitabine (226) · Leucovorin (148) · Irinotecan (127) · Gemcitabine (118) · Bevacizumab (84) · Docetaxel (74) · Tegafur (49)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 23 phase 3 studies under way

Oxaliplatin is the comparator. A study of two new drugs counts under both.

2Rilvegostomig · AstraZeneca · next primary completion Apr 2029
1Mosunetuzumab · Hoffmann-La Roche
1Polatuzumab vedotin · Hoffmann-La Roche
1Toripalimab · Peking University
1Ipilimumab · Bristol-Myers Squibb
1Nivolumab · Bristol-Myers Squibb
1Capecitabine · UNICANCER · next primary completion Nov 2032
1Folfirinox · UNICANCER · next primary completion Nov 2032

Reaching primary completion within a year · 32, 6 in phase 3

Studies that test Oxaliplatin, phase 3 first.

Dec 2026Paediatric Hepatic International Tumour TrialPhase 3 · University of Birmingham
Dec 2026Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal CancerPhase 3 · Karolinska University Hospital
Jan 2027Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic CancerPhase 3 · Erasmus Medical Center
Mar 2027HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic CancerPhase 3 · Fudan University
Apr 2027Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction CancerPhase 2/3 · Ukrainian Society of Clinical Oncology
Sep 2027A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)Phase 2/3 · Merck Sharp & Dohme LLC
Nov 2026Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative ManagementPhase 2 · Memorial Sloan Kettering Cancer Center
Nov 2026Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI MalignanciesPhase 2 · University of Vermont Medical Center
Nov 2026Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaPhase 2 · Fudan University
Dec 2026Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction CancerPhase 2 · UNICANCER

Studies

Open first, then newest update. How each study uses Oxaliplatin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 855

See all 855 studies that test Oxaliplatin →

Given beside what is tested · 725 — Oxaliplatin is usual care or a partner of the new treatment

Showing 20 of 725.

As the comparator · 68 — what is tested is compared with Oxaliplatin

Showing 20 of 68.

What changed recently

From the registry's own updates since Oct 15, 2026.

Codes

What other systems call Oxaliplatin · ClinicalTrials.gg INT006652

MeSH (NLM) D000077150OxaliplatinConfirmed ClinicalTrials.gov, NLM, Wikidata
UNII (FDA) 04ZR38536JOXALIPLATINConfirmed FDA, NLM, Wikidata
RxNorm 32592Confirmed FDA, Wikidata
Wikidata Q422327oxaliplatinConfirmed FDA, NLM, Wikidata
NCI Thesaurus C1181OxaliplatinConfirmed FDA, Wikidata
DrugBank DB00526One source Wikidata

System	Code	Name there	Checked by
MeSH (NLM)	D000077150	Oxaliplatin	Confirmed ClinicalTrials.gov, NLM, Wikidata
UNII (FDA)	04ZR38536J	OXALIPLATIN	Confirmed FDA, NLM, Wikidata
RxNorm	32592	—	Confirmed FDA, Wikidata
Wikidata	Q422327	oxaliplatin	Confirmed FDA, NLM, Wikidata
NCI Thesaurus	C1181	Oxaliplatin	Confirmed FDA, Wikidata
DrugBank	DB00526	—	One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.